GSA Capital Partners LLP Purchases New Shares in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

GSA Capital Partners LLP acquired a new position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 30,423 shares of the biopharmaceutical company’s stock, valued at approximately $143,000. GSA Capital Partners LLP owned approximately 0.05% of Vanda Pharmaceuticals at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Nantahala Capital Management LLC lifted its position in Vanda Pharmaceuticals by 57.3% during the second quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company’s stock valued at $9,003,000 after purchasing an additional 580,265 shares during the period. Profit Investment Management LLC grew its holdings in shares of Vanda Pharmaceuticals by 159.3% in the second quarter. Profit Investment Management LLC now owns 571,324 shares of the biopharmaceutical company’s stock worth $3,228,000 after acquiring an additional 351,000 shares during the period. Dimensional Fund Advisors LP grew its position in Vanda Pharmaceuticals by 17.0% during the second quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock valued at $11,379,000 after buying an additional 292,172 shares during the period. Monaco Asset Management SAM purchased a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth $1,090,000. Finally, AQR Capital Management LLC grew its stake in shares of Vanda Pharmaceuticals by 181.7% during the 2nd quarter. AQR Capital Management LLC now owns 75,889 shares of the biopharmaceutical company’s stock valued at $429,000 after acquiring an additional 48,945 shares during the period. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Insiders Place Their Bets

In related news, Director Stephen Ray Mitchell sold 5,000 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the completion of the transaction, the director now owns 44,857 shares in the company, valued at $231,910.69. The trade was a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 8.90% of the company’s stock.

Analysts Set New Price Targets

VNDA has been the subject of a number of research analyst reports. HC Wainwright began coverage on shares of Vanda Pharmaceuticals in a report on Thursday, October 31st. They set a “buy” rating and a $18.00 price objective for the company. Cantor Fitzgerald upped their target price on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Finally, StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a research report on Monday. They issued a “hold” rating on the stock.

Vanda Pharmaceuticals Stock Performance

Shares of Vanda Pharmaceuticals stock opened at $5.05 on Tuesday. The firm has a 50-day simple moving average of $4.80 and a two-hundred day simple moving average of $5.26. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.46 and a fifty-two week high of $6.75. The company has a market cap of $294.46 million, a P/E ratio of -18.29 and a beta of 0.77.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.